Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
Perrigo Company plc director Albert Manzone reported routine equity compensation activity. On May 13, he received 16,681 Restricted Stock Units (RSUs), each convertible into one ordinary share and scheduled to vest on May 13, 2027. On May 14, 7,305 RSUs vested and were exercised into ordinary shares, and 3,507 shares were withheld at $10.84 per share to cover tax obligations. Following these transactions, he holds 16,353 ordinary shares directly.
Perrigo Company plc director Bradley A. Alford reported routine equity compensation activity. On May 13 2026, he received 16,681 Restricted Stock Units, each representing a right to one ordinary share. On May 14 2026, 7,305 RSUs vested and were converted into the same number of ordinary shares.
On May 15 2026, 3,507 ordinary shares were surrendered at $10.84 per share to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Alford directly owned 44,958.148 ordinary shares.
Perrigo Company plc director Donal O'Connor reported routine equity compensation activity. On May 14 2026, he exercised Restricted Stock Units to acquire 7,305 Ordinary Shares and had 3,507 Ordinary Shares withheld at $10.84 per share to cover tax obligations. Following these transactions, he directly holds 37,942 Ordinary Shares and indirectly holds 1,198 Ordinary Shares through an Approved Retirement Fund. On May 13 2026, he also received a grant of 16,681 Restricted Stock Units, each representing a contingent right to one Ordinary Share, with vesting described in the footnotes.
Perrigo Company director Orlando D. Ashford reported compensation-related share movements. On May 13 2026, he received 24,363 Restricted Stock Units (RSUs), each representing a right to one ordinary share, scheduled to vest on May 13 2027.
On May 14 2026, 10,669 RSUs converted into the same number of ordinary shares, treated as a derivative exercise at a reference price of $10.84 per share. To cover tax obligations, 5,122 ordinary shares were withheld the same day as a tax-withholding disposition, rather than an open-market sale. After these transactions, Ashford directly held 27,717 ordinary shares, reflecting a net increase in ownership driven by equity compensation.
Perrigo Company plc director Kevin Francis Egan reported compensation-related equity activity, not open-market trading. On May 13, 2026, he received a grant of 16,681 Restricted Stock Units (RSUs), each representing one ordinary share and vesting on future dates as disclosed.
On May 14, 2026, 7,305 RSUs were converted into the same number of ordinary shares, and 3,507 ordinary shares were disposed of to cover tax obligations at a value of $10.84 per share. Following the tax-withholding disposition, 3,798 ordinary shares from that vesting event remained directly held. No remaining derivative position from the exercised RSUs is shown in this filing.
Perrigo Company plc director Jonas Samuelson reported compensation-related equity activity involving Restricted Stock Units (RSUs) and ordinary shares. On May 13 2026, he received a grant of 16,681 RSUs, each representing a contingent right to one ordinary share and scheduled to vest on May 13 2027.
On May 14 2026, 7,305 RSUs vested and were converted into ordinary shares. To satisfy tax obligations, 3,507 ordinary shares were disposed of at $10.84 per share through a tax-withholding transaction. Following these transactions, Samuelson directly owned 5,392 ordinary shares, with the new 16,681-unit RSU award remaining outstanding and unexercised.
Perrigo Company plc director Jonas Samuelson filed an amended Form 4 to correct a prior report of shares withheld to cover taxes on vested restricted stock units. On 6 March 2026, 3,066 Restricted Stock Units converted into 3,066 ordinary shares, and 1,472 ordinary shares were disposed of to satisfy tax-withholding obligations, not through an open-market sale. Following these transactions, Samuelson holds 1,594 ordinary shares directly.
T. Rowe Price Associates, Inc. reports beneficial ownership of 14,016,148 shares of Perrigo Co plc common stock, representing 10.2% of the class. The filing states sole voting power for 13,658,349 shares and sole dispositive power for 13,707,794.
T. Rowe Price Associates, Inc. amends its Schedule 13G/A to report ownership in Perrigo Co plc common stock. The filing states 13,376,708 shares beneficially owned, representing 9.7% of the class. It shows sole voting power of 13,327,263 and sole dispositive power of 13,376,708. The filing also identifies T. Rowe Price Mid‑Cap Value Fund with 7,498,410 shares (5.4%). The filing is signed by a T. Rowe Price Vice President.
Perrigo Company plc reported a sharp first‑quarter loss driven by large non‑cash impairments and restructuring costs. Net sales were $969.2 million, down from $1,043.9 million a year earlier, as Self Care, Specialty Care and All Other all declined modestly while Infant Formula was roughly flat.
The company recorded $330.8 million of goodwill impairments tied to Women’s Health, Infant Formula and Oral Care reporting units, plus $75.1 million of restructuring charges, turning operating income of $46.9 million last year into an operating loss of $372.3 million. Net loss from continuing and discontinued operations widened to $398.6 million, or $2.87 per diluted share, compared with a $6.4 million loss, or $0.05 per share, in the prior‑year period.
Cash used in operating activities was $113.6 million, and cash and cash equivalents fell to $357.2 million from $531.6 million at year‑end 2025. Total borrowings were $3,632.5 million, including $970.0 million of term loans and $2,262.2 million of notes and bonds. Perrigo also completed an amended credit agreement, drew $427.6 million on its revolver to repay Term Loan A, and completed the sale of its Dermacosmetics business after quarter‑end for up to €332.6 million in consideration.